Therapeutic proteins such as antibodies constitute the most rapidly growing class of
pharmaceuticals for use in diverse clinical settings including cancer, chronic inflammatory …

Therapeutic proteins such as antibodies are playing an increasingly prominent role in the
treatment of numerous diseases including cancer and rheumatoid arthritis. However, these …

Protein aggregation remains a major area of focus in the production of monoclonal
antibodies. Improving the intrinsic properties of antibodies can improve manufacturability …

Therapeutic antibodies of many different IgG subclasses (IgG1, IgG2 and IgG4) are used in
the treatment of various cancers, rheumatoid arthritis and other inflammatory and infectious …

Monoclonal antibodies are attractive therapeutics for treating a wide range of human
disorders due to their exquisite binding specificity and high binding affinity. However, a …

Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …

The ability of antibodies to bind to target molecules with high affinity and specificity has led
to their widespread use in diagnostic and therapeutic applications. Nevertheless, a limitation …

Human monoclonal antibodies often display limited thermodynamic and colloidal stabilities.
This behavior hinders their production, and places limitations on the development of novel …

Antibodies are used extensively in diagnostics and as therapeutic agents. Achieving high-
affinity binding is important for expanding detection limits, extending dissociation half-times …

For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …